Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On

Generation of T Cells with Reduced Off-Target Cross-Reactivities by Engineering Co-Signaling Receptors

January 5, 2026

[Nature Biomedical Engineering] The authors showed that T cell cross-reactivity can be controlled by the co-signalling molecules CD5, CD8, and CD4, without modifying the T cell receptor.

De Novo H3.3K27M-Altered Diffuse Midline Glioma in Human Brainstem Organoids to Dissect GD2 CAR T Cell Function

January 5, 2026

[Nature Cancer] Scientists developed an FGF4-driven human brainstem organoid model, which we used to genetically engineer H3.3K27M-altered diffuse midline glioma.

CD96 as a Therapeutic Target for CAR T Cell Therapy in Acute Myeloid Leukemia

January 5, 2026

[Molecular Therapy] Researchers developed a panel of CD96-CAR T cells using single-chain variable fragments derived from various monoclonal antibodies, incorporating distinct transmembrane and costimulatory domains.

AAV9 Gene Therapy Optimization for SMARD1/CMT2S: Safety and Long-Term Efficacy Comparison of Two Vectors in a SMARD1 Preclinical Model

January 5, 2026

[Journal of Biomedical Science] Investigators compared the efficacy of two novel, optimized AAV9-Immunoglobulin Mu DNA Binding Protein 2 vectors, utilizing either the chicken β-actin or a truncated form of the methyl-CpG-binding protein 2 promoter.

Affinity-Matured CD72-Targeting Nanobody CAR T Cells Enhance Elimination of Antigen-Low B-Cell Malignancies

January 5, 2026

[Journal For Immunotherapy of Cancer] CAR T cells were generated via lentiviral transduction. In vitro cytotoxicity assays were performed using luciferase-labeled cell lines.

mRNA-Based CAR T Cell Engineering: Unmodified mRNA Enables High CAR Expression without Innate Immune Activation in T Cells

January 5, 2026

[Molecular Therapy - Nucleic Acids] Immune responses toward mRNA were evaluated across five primary human cell types. Remarkably, T cells, unlike other immune and non-immune cell types tested, exhibited no immune activation by unmodified mRNA.

Targeted Gene Transfer into Developmentally Defined Cell Populations of the Primate Brain

January 5, 2026

[Cell Reports] Scientists presented a minimally invasive method to introduce transgenes widely across the primate cerebral cortex using ultrasound-guided fetal intracerebroventricular viral injections.

CAR T Cells Targeting B7H3 Demonstrate Potent Preclinical Activity against AML and ESCC

January 5, 2026

[International Immunopharmacology] Researchers described B7H3-targeted CAR-T cells constructed using the single-chain variable fragment of an anti-B7H3 antibody and systematically evaluated their safety and efficacy in vitro and in mice models of acute myeloid leukemia and esophageal squamous cell carcinoma.

Target Choice and Exon Skipping Regulate CRISPR-Directed Gene Editing of NRF2 in Head/Neck and Esophageal Cancer Cells

January 5, 2026

[Molecular Therapy Oncology] Investigators disabled specific endpoints of NRF2 in an attempt to restore chemo-sensitivity in head/neck and esophageal cancer cells. They identified two targeting characteristics that regulate the effectiveness of this approach.

CAR T Cell Exhaustion in Cancer over the Past Decade: Mitochondrial Metabolism as a Target for Counteraction

January 5, 2026

[Cancer Letters] The authors review the current challenges facing the clinical application of CAR-T therapy in cancers and summarize mitochondrial-centered approaches to overcome some of these obstacles by optimizing mitochondrial metabolic pathways.

CAR T Cells As Novel Therapeutic Strategy for Multiple Sclerosis and Other Neuroimmune Disorders

January 5, 2026

[Journal of Neuroinflammation] Investigators synthesize the current evidence supporting the use of CAR T-cell therapy in neuroinflammatory diseases and explore its potential to redefine treatment paradigms by shifting from chronic immunosuppression to long-term immune tolerance.

Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson’s Disease

January 5, 2026

[Kenai Therapeutics/BIOCOM (PR Newswire)] Kenai Therapeutics announced that the CIRM awarded an $8 million grant to Dr. Howard J. Federoff. This funding will support the continued clinical advancement of RNDP-001, an off-the-shelf, allogeneic neuron replacement cell therapy.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.